KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBT Margin (2016 - 2025)

Jazz Pharmaceuticals has reported EBT Margin over the past 16 years, most recently at 17.4% for Q4 2025.

  • Quarterly results put EBT Margin at 17.4% for Q4 2025, up 516.0% from a year ago — trailing twelve months through Dec 2025 was 11.42% (down 2298.0% YoY), and the annual figure for FY2025 was 14.71%, down 2627.0%.
  • EBT Margin for Q4 2025 was 17.4% at Jazz Pharmaceuticals, up from 0.8% in the prior quarter.
  • Over the last five years, EBT Margin for JAZZ hit a ceiling of 22.33% in Q1 2021 and a floor of 70.34% in Q2 2025.
  • Median EBT Margin over the past 5 years was 2.25% (2022), compared with a mean of 1.25%.
  • Biggest five-year swings in EBT Margin: skyrocketed 6147bps in 2021 and later tumbled -8381bps in 2025.
  • Jazz Pharmaceuticals' EBT Margin stood at 5.0% in 2021, then tumbled by -600bps to 34.97% in 2022, then soared by 117bps to 6.08% in 2023, then surged by 101bps to 12.24% in 2024, then skyrocketed by 42bps to 17.4% in 2025.
  • The last three reported values for EBT Margin were 17.4% (Q4 2025), 0.8% (Q3 2025), and 70.34% (Q2 2025) per Business Quant data.